已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis

痴呆 荟萃分析 医学 危险系数 科克伦图书馆 队列研究 阿尔茨海默病 疾病 系统回顾 老年学 梅德林 置信区间 内科学 政治学 法学
作者
Chih‐Sung Liang,Dian‐Jeng Li,Fu‐Chi Yang,Ping‐Tao Tseng,André F. Carvalho,Brendon Stubbs,Trevor Thompson,Christoph Mueller,Jae Il Shin,Joaquim Raduà,Robert Stewart,Tarek K. Rajji,Yu‐Kang Tu,Tien‐Yu Chen,Ta‐Chuan Yeh,Chia‐Kuang Tsai,Chia‐Ling Yu,Chih‐Chuan Pan,Che‐Sheng Chu
出处
期刊:The Lancet Healthy Longevity [Elsevier]
卷期号:2 (8): e479-e488 被引量:103
标识
DOI:10.1016/s2666-7568(21)00140-9
摘要

People with dementia die prematurely. Identifying differences in mortality rates between different types of dementia might aid in the development of preventive interventions for the most vulnerable populations. The aim of this study was to compare the difference in mortality rates between individuals without dementia and individuals with various types of dementia.For this systematic review and meta-analysis, we did a systematic search of MEDLINE, PubMed, Embase, and Cochrane Library from inception to July 11, 2020, for cross-sectional or cohort studies that assessed mortality and survival-related outcomes among people with different types of dementia compared with people without dementia. Single-arm studies without comparison groups and autopsy studies or family studies that used a selected sample were excluded. The Newcastle-Ottawa Scale was used by two authors (D-JL and C-SC) independently to measure the methodological quality of included studies, and two authors (F-CY and P-TT) independently extracted data. We assessed differences in all-cause mortality rate and survival time from dementia diagnosis between individuals without dementia, individuals with Alzheimer's disease, and individuals with non-Alzheimer's disease dementias. The secondary outcomes were age at death and survival time from disease onset. Random-effects meta-analyses were done. Effect sizes included hazard ratios (HRs) and mean differences (MDs) with 95% CIs. Potential moderators, including age-associated moderators, were identified through meta-regression and subgroup analyses. This study is registered with PROSPERO, CRD42020198786.Our database search identified 11 973 records, and we included 78 eligible studies in our analyses, encompassing 63 125 individuals with dementia and 152 353 controls. Individuals with any type of dementia had a higher mortality rate than individuals without dementia (HR 5·90, 95% CI 3·53 to 9·86), and the HR for all-cause mortality was highest for Lewy body dementia (17·88, 5·87 to 54·46). After diagnosis, the mean survival time for people with Alzheimer's disease was 5·8 years (SD 2·0). Compared with people with Alzheimer's disease, a diagnosis of any non-Alzheimer's disease dementia was associated with a higher risk of all-cause mortality (HR 1·33, 1·21 to 1·46), a shorter survival time from diagnosis (MD -1·12 years, 95% CI -1·52 to -0·72), and a younger age at death (-1·76 years, -2·66 to -0·85). Survival time from disease onset was also shorter in people with non-Alzheimer's dementia, across types, compared with people with Alzheimer's disease, but the subgroup analysis revealed that this difference was only significant for vascular dementia (MD -1·27 years, -1·90 to -0·65) and dementia with Lewy bodies (MD -1·06 years, -1·68 to -0·44). The interactions between age and several survival-related outcomes were significant. 39 (50%) of the 78 included studies were rated as good quality, and large heterogeneity (I2>75%) was observed for most of the study outcomes.Alzheimer's disease is the most common type of dementia and one of the major causes of mortality worldwide. However, the findings from the current study suggest that non-Alzheimer's disease dementias were associated with higher morality rates and shorter life expectancy than Alzheimer's disease. Developing tailored treatment and rehabilitation programmes for different types of dementia is important for mental health providers, patients, and their families.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
yuqinghui98完成签到 ,获得积分10
4秒前
柯伯云给柯伯云的求助进行了留言
4秒前
冷静的伊完成签到,获得积分10
4秒前
5秒前
zhangling发布了新的文献求助10
7秒前
大模型应助hhc采纳,获得10
14秒前
zhangling完成签到,获得积分10
16秒前
Rr完成签到,获得积分10
19秒前
YZH应助柯伯云采纳,获得20
22秒前
66发完成签到,获得积分10
24秒前
Rw完成签到 ,获得积分10
25秒前
少虡发布了新的文献求助10
26秒前
123完成签到 ,获得积分10
26秒前
虚幻灵薇完成签到 ,获得积分10
35秒前
ding应助wupa采纳,获得10
41秒前
Wee完成签到 ,获得积分10
41秒前
科研通AI2S应助Hum0ro98采纳,获得10
45秒前
科研通AI2S应助Hum0ro98采纳,获得10
45秒前
52秒前
53秒前
55秒前
上官若男应助科研通管家采纳,获得10
58秒前
杳鸢应助科研通管家采纳,获得10
58秒前
赘婿应助科研通管家采纳,获得10
58秒前
科研通AI2S应助科研通管家采纳,获得10
58秒前
zxt应助科研通管家采纳,获得10
58秒前
粿粿一定行完成签到 ,获得积分10
1分钟前
慕青应助机智的书竹采纳,获得10
1分钟前
foxdaopo完成签到,获得积分10
1分钟前
Ava应助Wander_Li采纳,获得10
1分钟前
涛哥来科研完成签到 ,获得积分10
1分钟前
1分钟前
茜茜完成签到,获得积分10
1分钟前
樱悼柳雪完成签到,获得积分10
1分钟前
1分钟前
且从容完成签到,获得积分10
1分钟前
YZH给柯伯云的求助进行了留言
1分钟前
dengxu发布了新的文献求助10
1分钟前
虚心千凡发布了新的文献求助10
1分钟前
高分求助中
Earth System Geophysics 1000
Semiconductor Process Reliability in Practice 650
Studies on the inheritance of some characters in rice Oryza sativa L 600
Medicina di laboratorio. Logica e patologia clinica 600
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
Language injustice and social equity in EMI policies in China 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3207671
求助须知:如何正确求助?哪些是违规求助? 2856984
关于积分的说明 8108052
捐赠科研通 2522565
什么是DOI,文献DOI怎么找? 1355756
科研通“疑难数据库(出版商)”最低求助积分说明 642234
邀请新用户注册赠送积分活动 613602